Miltenyi Biotec, a leading global biotechnology company headquartered in Germany (DE), has been at the forefront of innovative cell and gene therapy solutions since its founding in 1989. With a strong presence in Europe, North America, and Asia, the company focuses on developing advanced technologies for biomedical research and clinical applications. Specialising in cell separation, cell culture, and gene editing, Miltenyi Biotec offers unique products such as the MACS® Technology and the CliniMACS® Prodigy system, which streamline workflows and enhance research outcomes. Renowned for its commitment to quality and innovation, the company has achieved significant milestones, including the development of cutting-edge tools that support personalised medicine. Miltenyi Biotec's dedication to advancing scientific knowledge has solidified its position as a trusted partner in the life sciences industry, making it a key player in the ongoing evolution of therapeutic solutions.
How does Miltenyi Biotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Miltenyi Biotec's score of 25 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Miltenyi Biotec, headquartered in Germany, has made significant commitments towards reducing its carbon emissions, although specific emissions data for the most recent year is currently unavailable. The company has committed to achieving net-zero emissions across all scopes by 2050, with a start year of 2023. This long-term target aligns with industry standards and reflects a proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector. Miltenyi Biotec's near-term targets are classified as "Committed," indicating a serious dedication to implementing strategies that will contribute to their net-zero goal. While specific reduction percentages have not been disclosed, the commitment to net-zero emissions demonstrates the company's intention to significantly lower its carbon footprint over the coming decades. As the company progresses towards its climate commitments, it will be essential to monitor their initiatives and any future emissions data to assess their impact on global climate goals.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Miltenyi Biotec is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.